Key statistics dashboard for Alterity Therapeutics Limited (ATHE). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease.
Stock Data
| Price | $3.85 |
| Market Cap | $65M |
| Enterprise Value | $55.3M |
| Beta | -0.07 |
| Exchange | NASDAQ |
| Country | AU |
Valuation Multiples
| P/E Ratio | -3.89 |
| Price / Book | 2.19 |
| P/S | 0.00 |
| EV/EBITDA | -1.95 |
| EV/Sales | 0.00 |
| EV/FCF | 0.00 |
| P/FCF | 0.00 |
| Earnings Yield | -25.31% |
| FCF Yield | 0.00% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -48.25% |
| Return on Assets | -50.85% |
| Return on Invested Capital | -57.61% |
| Return on Capital Employed | -66.30% |
Financial Health
| Current Ratio | 14.52 |
| Quick Ratio | 14.52 |
| Cash Ratio | 11.82 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.42% |
| Net Debt / EBITDA | 1.31 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 117.86 |
| Cash per share | 102.94 |
| FCF per share | 0.00 |
| Tangible Book Value per share | 117.86 |
| Dividend per share | 0.00 |
Related companies: ANVS · BTAI · DYAI · EVAX · GBIO · IGC · LIMN
Explore sector: Healthcare · Biotechnology
More sections of ATHE: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks